Liraglutide in the Treatment of Type 1 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 1, 2012

Primary Completion Date

April 1, 2014

Study Completion Date

December 1, 2014

Conditions
Type 1 Diabetes
Interventions
DRUG

Liraglutide

"Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards."

DRUG

Placebo

"Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards."

Trial Locations (1)

14221

Diabetes-Endocrinology Center of Western NY, Williamsville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

University at Buffalo

OTHER

NCT01722266 - Liraglutide in the Treatment of Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter